Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

February 24, 2026

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗

February 23, 2026

The company is studying its approved drug for many other indications.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

February 20, 2026

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

February 11, 2026

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Why Are IOVA Shares Rising Today? ↗

November 06, 2025

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

February 05, 2026

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

IOVA Shares Jump 8% — What’s Retail Expecting? ↗

January 26, 2026

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Via Stocktwits

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

January 16, 2026

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗

December 29, 2025

Don't get too excited about their prospects.

Via The Motley Fool

Topics Death

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 19, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗

December 07, 2025

This juicy upside potential comes at a cost.

Via The Motley Fool

Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Iovance (IOVA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

November 21, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗

November 11, 2025

Iovance has a long way to go to get to a break-even point, but the company has been showing progress.

Via The Motley Fool

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗

November 07, 2025

Wall Street may be overestimating these companies' potential.

Via The Motley Fool

Top movers in Thursday's session ↗

November 06, 2025

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026

November 06, 2025

Via AB Newswire

Top stock movements in today's session. ↗

November 06, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

Gapping stocks in Thursday's session ↗

November 06, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

November 06, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗

November 05, 2025

Via Benzinga

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

November 03, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.